ClinicalTrials.gg
Not yet recruitingNCT07146217Updated Aug 28, 2025

Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection

A Phase 2 interventional study of Likmez® (metronidazole) Oral Suspension in Bacterial Infections, sponsored by Saptalis Pharmaceuticals LLC. Not yet recruiting at 3 sites in United States. Open to participants aged 12 Months to 4 Years. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Saptalis Pharmaceuticals LLC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
12 Months to 4 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 181 studies in Bacterial Infections with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Bacterial Infections · United States.

Planned enrollment
115th of 151
30 · median 62
Started
2025
with 5 others
Phase 2
26 of 181
1 open now
Primary completion
2026-07
later than 2 of 14 live
Registered
177th of 181
by date

Among the 181 studies in Bacterial Infections with a site in United States, this one is the 115th largest by planned enrollment of the 151 interventional ones that give a count, is one of 6 that started in 2025, is one of 26 in phase 2, reaches primary completion later than 2 of the 14 other live ones, and was the 177th registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

12 of the 181 studies in Bacterial Infections with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 12 Months to 4 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Bacterial Infections with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, single-arm, pharmacokinetic and safety study of Likmez® in pediatric patients aged 12 months to \<4 years with anaerobic bacterial infection

03

Conditions studied

  • Bacterial Infections

Browse trials for

Keywords

  • Anaerobic Bacterial Infection
04

Who can participate

Ages eligible
12 Months to 4 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between ≥ 12 months and \< 4 years till the time of dosing in the study
  • Sufficient venous access to permit cannulation for required blood sample collection.
  • Ability to swallow oral liquids.
  • Clinical diagnosis with suspected or culture-confirmed anaerobic bacterial infection with pathogens known to be sensitive to metronidazole and requiring treatment for any of the below mentioned infections:

    1. Septicaemia and Bacteraemia
    2. Intra-abdominal infections (including peritonitis, intra-abdominal abscess, and liver abscess)
    3. Bone and joint infections (including osteomyelitis)
    4. Lower respiratory tract infections (including pneumonia, empyema, and lung abscess)
  • Patients with clinical diagnosis of polymicrobial infection who can be administered Likmez® with other antibacterial agents without drug-drug interactions. Note: These patients will be allowed concomitant administration with other antibacterial drugs, not having an interaction with metronidazole (Refer APPENDIX B: List of Antibiotic Drugs Having Interaction with Metronidazole, for the list of antibiotic drugs having interaction with metronidazole). If co-administration of such medications cannot be avoided, PI should consider taking steps to minimize the risk of /QTc interval prolongation and torsade de pointes (TdP), such as electrolyte monitoring and repletion, and monitoring, especially in patients with additional risk factors for TdP.
  • Any of the above mentioned clinical conditions, which would allow them to initiate the treatment with IV or oral anti-bacterial drugs with activity against anaerobic bacteria (e.g., IV treatment such as a betalactam/beta-lactamase inhibitor or a cephalosporin plus metronidazole; or oral treatment such as amoxicillin, amoxicillin-clavulanate, or azithromycin) followed by treatment with i.e. Likmez® at 7.5 mg/kg, to complete the treatment course and are able to provide PK samples for the study.
  • Parents/legal guardians of the patient have provided Written prior to initiation of any protocol-specific procedures.

Exclusion criteria

Exclusion Criteria:

  • History of anaphylactic reaction to metronidazole or other nitroimidazole derivatives (e.g., tinidazole).
  • Presence of encephalopathy or peripheral neuropathy.
  • Presence or history of clinically significant convulsive seizure disorders.
  • Presence or history of any hematologic condition or blood dyscrasia which may result in leukopenia (even if leukocyte count is normal at screening).
  • Abnormal laboratory results for the following analyses showing any of the following abnormal results:

    1. (AST), alanine transaminase (ALT)>2 X the upper limit of the reference range
    2. WBC count \<3.0 X 109 /L
    3. Total ≥20 μmol/L (1.17 mg/dL); except in patients with isolated elevation of indirect bilirubin relating to Gilbert syndrome
    4. Estimated (eGFR) \<30 mL/min/1.73 m2 using the Bedside Schwartz methods for estimation (eGFR = 41.3 x height/serum creatinine (Scr), where height is in meters and Scr in mg/dL)
    5. \<8 g/dL
    6. \<100,000/μL
  • History or presence of any clinically significant disease or disorder that, in the opinion of the investigator, would put the patient at risk or would potentially influence the results of the study (e.g. evidence of gastrointestinal, hepatic, or renal disease that could affect absorption, distribution, metabolism, or excretion of the orally administered study drug).
  • Patients with a history of hereditary fructose intolerance (HFI) or rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.
  • Patients with a known sensitivity to glucose (e.g. patients with a diagnosis of diabetes or patients taking a ketogenic diet).
  • Patients with a history of Severe cutaneous adverse reactions (SCARs), including Stevens Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP).
  • Patients who have used disulfiram within the last two weeks prior to enrollment in study.
  • Patients who have consumed products containing propylene glycol within a week prior to enrollment in study and who wish to continue products containing propylene glycol during the study and for at least three days after the end of treatment period.
  • Patients with known status of Cockayne syndrome.
  • Patients with treatment with any another drug that is known to have pharmacokinetic interaction [For example: barbiturates such as phenytoin or phenobarbital] with metronidazole, within 30 days prior to enrollment or within 5.5 half-lives of the drug, (whichever is longer), until the end of study.
  • Previous exposure to metronidazole within 30 days of enrollment.
  • Patients with a known history of virus (HBV), virus (HCV), (HIV), and latent tuberculosis (TB) infections.
  • Previous participation in this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Likmez® (metronidazole) Oral Suspension

    Drug: Likmez® (metronidazole) Oral Suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration [Cmax]

    Pharmacokinetic profile of metronidazole and hydroxy-metronidazole (primary metabolite) measured by Cmax

    Time frame: Day 1 at Pre-dose (0.00 hour, within 01 hour prior to dosing) and at 01.00, 02.00, 4.00 and 6.00 hours post-dose

  2. Time to reach at maximum plasma concentration [Tmax]

    Pharmacokinetic profile of metronidazole and hydroxy-metronidazole (primary metabolite) measured by Tmax

    Time frame: Day 1 at Pre-dose (0.00 hour, within 01 hour prior to dosing) and at 01.00, 02.00, 4.00 and 6.00 hours post-dose

  3. Area under the concentration-time curve from time 0 to time 't' '[AUC0-t]

    Pharmacokinetic profile of metronidazole and hydroxy-metronidazole (primary metabolite) measured by AUC0-t

    Time frame: Day 1 at Pre-dose (0.00 hour, within 01 hour prior to dosing) and at 01.00, 02.00, 4.00 and 6.00 hours post-dose

  4. Volume of distribution [Vd/F]

    Pharmacokinetic profile of metronidazole and hydroxy-metronidazole (primary metabolite) measured by Vd/F

    Time frame: Day 1 at Pre-dose (0.00 hour, within 01 hour prior to dosing) and at 01.00, 02.00, 4.00 and 6.00 hours post-dose

  5. Apparent clearance of drug from plasma [CLTotal/F]

    Pharmacokinetic profile of metronidazole and hydroxy-metronidazole (primary metabolite) measured by CLTotal/F. The CLTotal will be calculated by dividing the dose by the AUC for the given dosing interval \[Dose/ AUC0-Tau\]

    Time frame: Day 1 at Pre-dose (0.00 hour, within 01 hour prior to dosing) and at 01.00, 02.00, 4.00 and 6.00 hours post-dose

Secondary outcomes

  1. Comparison of AUC0-t in Pediatric Patients Without Prior IV Metronidazole to Adult Single-Dose PK Data

    Time frame: Day 1 at Pre-dose (0.00 hour, within 01 hour prior to dosing) and at 01.00, 02.00, 4.00 and 6.00 hours post-dose

  2. Comparison of Cmax in Pediatric Patients Without Prior IV Metronidazole to Adult Single-Dose PK Data

    Time frame: Day 1 at Pre-dose (0.00 hour, within 01 hour prior to dosing) and at 01.00, 02.00, 4.00 and 6.00 hours post-dose

  3. Comparison of AUC0-t in Pediatric Patients With Prior IV Metronidazole to Adult Steady-State PK Data

    Time frame: Day 1 at Pre-dose (0.00 hour, within 01 hour prior to dosing) and at 01.00, 02.00, 4.00 and 6.00 hours post-dose

  4. Comparison of Cmax in Pediatric Patients With Prior IV Metronidazole to Adult Steady-State PK Data

    Time frame: Day 1 at Pre-dose (0.00 hour, within 01 hour prior to dosing) and at 01.00, 02.00, 4.00 and 6.00 hours post-dose

  5. Number of Participants With Adverse Events as Assessed by CTCAE v5.0

    Time frame: From screening to end of study, up to 26 days

  6. Number of Participants with Changes in Systolic Blood Pressure and Diastolic Blood Pressure

    Time frame: From screening to end of study, up to 26 days

  7. Number of Participants with Changes in Respiratory Rate

    Time frame: From screening to end of study, up to 26 days

  8. Number of Participants with Changes in Pulse Rate

    Time frame: From screening to end of study, up to 26 days

  9. Number of Participants with Changes in Body Temperature

    Time frame: From screening to end of study, up to 26 days

  10. Number of Participants with Changes of P wave in Electrocardiogram (ECG)

    Time frame: From screening to end of study, up to 26 days

  11. Number of Participants with Changes of QRS complex in Electrocardiogram (ECG)

    Time frame: From screening to end of study, up to 26 days

  12. Number of Participants with Changes of T wave in Electrocardiogram (ECG)

    Time frame: From screening to end of study, up to 26 days

  13. Number of Participants with Changes in Clinical Laboratory Values

    Time frame: From screening to end of study, up to 26 days

  14. Number of Participants With Abnormal Physical Examination Findings

    Time frame: From screening to end of study, up to 26 days

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Jul 2026, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Aug 28, 2025
StartEst.
Aug 2025
Primary completionEst.
Jul 2026
CompletionEst.
Oct 2026
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07146217
Lead sponsor
Saptalis Pharmaceuticals LLC
Collaborators
CBCC Global Research
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Aug 2025 (estimated)
Primary completion
Jul 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Aug 28, 2025

Study contacts

Santhy John
Contact
santhy.john@saptalis.com
631-231-2751 ext. 111
Veera Somasani
Contact
veera.somasani@saptalis.com
631-231-2751 ext. 111
Polireddy Dondeti, PhD
study chair · President & CEO

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metronidazole

Start the discussion